[go: up one dir, main page]

MX2009009515A - Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. - Google Patents

Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.

Info

Publication number
MX2009009515A
MX2009009515A MX2009009515A MX2009009515A MX2009009515A MX 2009009515 A MX2009009515 A MX 2009009515A MX 2009009515 A MX2009009515 A MX 2009009515A MX 2009009515 A MX2009009515 A MX 2009009515A MX 2009009515 A MX2009009515 A MX 2009009515A
Authority
MX
Mexico
Prior art keywords
treating
preventing
compounds
cyanopyrrole
modulation
Prior art date
Application number
MX2009009515A
Other languages
English (en)
Inventor
Andrew Fensome
Casey Cameron Mccomas
Michael Anthony Marella
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009009515A publication Critical patent/MX2009009515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

En una modalidad, se describen compuestos de la siguiente estructura, en donde R1 a R7 son descritos aquí. Fórmula I: (ver fórmula I) también se proveen métodos para la preparación de estos compuestos y métodos de anticoncepción; tratamiento o prevención de fibroides; tratamiento o prevención de leiomioma uterino; tratamiento o prevención de endometriosis, sangrado disfuncional, y síndrome de ovario policístico; tratamiento o prevención de carcinomas dependientes de hormona, proveer terapia de reemplazo de hormona; estimulación de consumo de alimentos; sincronización de estro, y tratamiento de síntomas relacionados con el ciclo usando los compuestos descritos aquí.
MX2009009515A 2007-03-06 2008-03-04 Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. MX2009009515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90523907P 2007-03-06 2007-03-06
PCT/US2008/002829 WO2008109055A2 (en) 2007-03-06 2008-03-04 Cyanopyrrole sulfonamides useful for modulation of the progesterone receptor

Publications (1)

Publication Number Publication Date
MX2009009515A true MX2009009515A (es) 2009-09-16

Family

ID=39719009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009515A MX2009009515A (es) 2007-03-06 2008-03-04 Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.

Country Status (9)

Country Link
US (2) US7723332B2 (es)
EP (1) EP2137145A2 (es)
JP (1) JP2010520282A (es)
AR (1) AR065520A1 (es)
CA (1) CA2679564A1 (es)
CL (1) CL2008000673A1 (es)
MX (1) MX2009009515A (es)
TW (1) TW200848019A (es)
WO (1) WO2008109055A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7751863B2 (en) 2007-02-06 2010-07-06 Glumetrics, Inc. Optical determination of ph and glucose
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
AR070120A1 (es) * 2008-01-11 2010-03-17 Wyeth Corp Derivados de aril sulfonamida que contienen o-sulfato y o-fosfato, utiles como inhibidores de beta-amiloide, proceso de preparacion de los mismos y composiciones farmaceuticas que los contienen.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230088D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
PE20070404A1 (es) 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor

Also Published As

Publication number Publication date
TW200848019A (en) 2008-12-16
WO2008109055A3 (en) 2008-10-30
US20080221201A1 (en) 2008-09-11
WO2008109055A2 (en) 2008-09-12
CA2679564A1 (en) 2008-09-12
EP2137145A2 (en) 2009-12-30
WO2008109055A8 (en) 2009-01-08
AR065520A1 (es) 2009-06-10
US20100204228A1 (en) 2010-08-12
JP2010520282A (ja) 2010-06-10
US7723332B2 (en) 2010-05-25
CL2008000673A1 (es) 2008-07-18

Similar Documents

Publication Publication Date Title
TW200716621A (en) Polymorph form II of tanaproget
TW200731969A (en) Use of progesterone receptor modulators
NZ597639A (en) 17-hydroxy-17-pentafluorethyl-estra-4,9
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
WO2008021339A3 (en) Pyrrolidine and related derivatives useful as pr modulators
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
MX2009001698A (es) Derivados de oxazolidona como moduladores pr.
TW200716129A (en) Micronized tanaproget, compositions, and methods of preparing the same
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
DE602005019905D1 (de) -modulatoren
ATE434434T1 (de) Zusammensetzungen mit mikronisiertem tanaproget
EA200702524A1 (ru) Нестероидные модуляторы рецептора прогестерона
SI1809602T1 (sl) Indolni derivati, uporabni kot modulatorji progesteronskega receptorja
PE20081803A1 (es) Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
EA201501000A1 (ru) Спироиндолиновые производные для применения в качестве антагонистов рецептора гонадотропин-рилизинг-гормона
UY30815A1 (es) Moduladores no esteroidales del receptor de progesterona

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration